Research Article
Higher Serum-Soluble α-Klotho Level Does Not Predict Longer Survival after Stroke
Table 1
Patient characteristics depending on plasma-soluble α-Klotho concentrations.
| | <487.7 () | 487.7–813.5 () | ≥813.5 () |
| | Soluble α-Klotho tertiles | | | | | Soluble α-Klotho (pg/mL) | 336.1 (200.7–420.3) | 636.4 (581.2–725.6) | 1055.7 (915.5–1271.7) | | Age (years) | | | | | Sex (men/women) | 33/39 | 35/39 | 31/40 | | Previous stroke or transient ischemic attack ( (%)) | 12 (16.7) | 16 (21.6) | 14 (19.7) | | Concomitant diseases | | | | | Hypertension ( (%)) | 63 (87.5) | 60 (81.1) | 63 (88.7) | | Ischemic heart disease ( (%)) | 16 (22.2) | 27 (36.5) | 20 (28.2) | | Atrial fibrillation ( (%)) | 16 (22.2) | 23 (31.1) | 27 (38.0) | | Obesity ( (%)) | 13 (18.1) | 9 (12.2) | 20 (28.2) | | Diabetes ( (%)) | 27 (37.5) | 28 (37.8) | 24 (33.8) | | Hypercholesterolemia ( (%)) | 35 (48.6) | 32 (43.2) | 34 (47.9) | | Medications before stroke | | | | | Aspirin ( (%)) | 36 (50.7) | 36 (48.6) | 35 (50.0) | | Statin therapy ( (%)) | 32 (44.4) | 26 (35.1) | 26 (36.6) | | Antithrombotic agents ( (%)) | 8 (11.1) | 13 (17.6) | 6 (8.5) | | Addictions | | | | | Active smokers ( (%)) | 17 (23.6) | 16 (21.6) | 12 (16.9) | | Addicted to alcohol ( (%)) | 4 (5.6) | 4 (5.4) | 2 (2.8) | | Type of stroke | | | | | Large vessel occlusion ( (%)) | 41 (56.9) | 33 (44.6) | 32 (45.1) | | Lacunar ( (%)) | 20 (27.8) | 20 (27.0) | 16 (22.5) | | Embolic ( (%)) | 11 (15.3) | 21 (28.4) | 23 (32.4) | | Laboratory findings | | | | | Total cholesterol (mmol/L) | | | | | LDL cholesterol (mmol/L) | | | | | HDL cholesterol (mmol/L) | | | | | Triglycerides (mmol/L) | 1.46 (1.12–2.16) | 1.34 (0.98–1.82) | 1.36 (1.06–1.85) | | Creatinine (μmol/L) | 80.9 (69.4–92.2) | 83.1 (69.7–99.0) | 78.5 (70.0–89.3) | | Estimated glomerular filtration rate—eGFR (mL/min/1.73 m2) | | | | | CKD ( or albuminuria) ( (%)) | 26 (36.1) | 28 (37.8) | 26 (36.6) | | C-reactive protein (mg/dL) | 5.31 (1.99–13.80) | 2.86 (1.10–8.21) | 4.36 (2.44–8.43) | | Calcium (mg/dL) | 2.34 (2.22–2.46) | 2.29 (2.15–2.46) | 2.29 (2.20–2.44) | | Phosphorus (mg/dL) | 1.09 (0.97–1.26) | 1.11 (0.95–1.36) | 1.16 (1.01–1.48) | | Intact parathyroid hormone (pg/mL) | 42.1 (28.8–60.6) | 35.9 (22.0–59.6) | 41.7 (29.7–56.3) | | Intact fibroblast growth factor 23—iFGF23 (pg/mL) | 40.3 (16.6–84.3) | 50.2 (12.6–83.6) | 66.4 (34.0–92.2) | | Klotho/iFGF23 | 6.8 (2.9–21.5) | 13.6 (8.3–51.9) | 18.8 (10.1–32.7) | | Overall survival (OS) and stroke-free survival (SFS) | | | | | 12-month OS ( (%)) | 60 (83.3) | 55 (74.3) | 51 (71.8) | | 24-month OS ( (%)) | 57 (79.2) | 46 (62.2) | 47 (66.2) | | 36-month OS ( (%)) | 45 (62.5) | 44 (59.5) | 39 (54.9) | | 12-month SFS ( (%)) | 60 (83.3) | 55 (74.3) | 51 (71.8) | | 24-month SFS ( (%)) | 57 (79.2) | 45 (60.8) | 46 (64.8) | | 36-month SFS ( (%)) | 44 (61.1) | 43 (58.1) | 36 (50.7) |
|
|
or median (lower quartile-upper quartile). . |
